Attralus
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
329 Oyster Point Blvd Fl 3, South San Fr...Phone Number
(415) 410-3268Website
www.attralus.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Attralus
Headquartered in San Francisco, California, Attralus is a biopharmaceutical company with a focus on systemic amyloidosis.Explore more
Attralus Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Attralus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Attralus has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Attralus has new funding data
Product Launch: Get notified when Attralus launches new products
Attralus, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Attralus is spiking on competitors!
Click to see if Attralus had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Attralus recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Attralus
Recommended Actions
Find VP level buyers at Attralus
Find 2 more new buyers
Compare Similar Companies to Attralus
Compare insights from companies similar to Attralus, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Attralus is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Attralus is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Attralus.
Attralus financials insights
Gather financial insights about Attralus, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$25M
2021
Series B
$116M
Attralus Tech Stack
A closer look at the technologies used by Attralus
See more technologies
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Product Development, Product Management, Legal Affairs, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Facilities Relocation / Expansion
Attralus is planning to move its offices in October 2022. The move will impact employees at their existing office located at 50 Francisco St, Suite #450, San Francisco, CA.
Funding
Funding
Attralus News & Media
Attralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
NAPLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Attralus, Inc., is a clinical stage biopharmaceutical company developing transformative medicines and diagnostics to improve the lives of patients with systemic amyloidosis. The Company announced the presentation of a phase 1/2 study of AT-02, (a novel pan-amyloid depleter IgG fusion protein) in AL patients at the upcoming 67th ASH Annual Meeting and Exposition in Orlando, FL on December 6-9, 2025.Attralus Presents New Data on Its Pan-Amyloid Diagnostic Imaging Candidates at ASNC 2025
NAPLES, Fla., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines and diagnostics to improve the lives of patients with systemic amyloidosis, announced five poster presentations and two oral presentations (from investigator-initiated trials), on the use of 124I-evuzamitide and AT-05 (99mTc-p5+14) , the company’s pan-amyloid binding diagnostic imaging agents in development for the diagnosis of systemic amyloidosis, at tAttralus Presents New Data on Its Pan-Amyloid Diagnostic Candidates at the 2025 American College of Cardiology (ACC) Annual Scientific Session
NAPLES, Fla., April 01, 2025 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines and diagnostics to improve the lives of patients with systemic amyloidosis, announced three poster presentations (from four investigator-initiated trials), on the use of 124I-evuzamitide, the company’s pan-amyloid binding imaging agent in development for the diagnosis of cardiac amyloidosis, and one poster presentation of encouraging new clinical data frAttralus Announces Enrollment of First Patient in Phase 3 Trial for the Pan-Amyloid Diagnostic 124I-evuzamitide (AT-01) for Cardiac Amyloidosis
NAPLES, Fla., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative products to improve the lives of patients with systemic amyloidosis, and Brigham and Women’s Hospital, Boston, MA, are pleased to announce the enrollment of the first patient in the Research with 124I-EVuzamitide to Elucidate Cardiac AmyLoidosis (REVEAL) study – A Phase 3 clinical trial of the investigational diagnostic imaging agent, 124I-evuzamitide (AT-01), in p
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Attralus
Sign Up For FreeTo access detailed company insights
Headquartered in San Francisco, California, Attralus is a biopharmaceutical company with a focus on systemic amyloidosis.... Read More
